欧洲肥胖研究协会（EASO）：第33届欧洲肥胖大会（ECO 2026）嘉宾演讲PPT合集（共24套打包）

1、Scan QR code or visit the web site below for:PosterPoster+slideshttps:/ WT et al.N Engl J Med 2025;393:635647;(2)Davies MJ et al.N Engl J Med 2025;393:648659;(3)Frias JP et al.Lancet 2023;402:720730;。

2、 PO4.002Early responders to semaglutide 7.2 mg:A post hoc analysis of the STEP UP trial in adults with obesityDror Dicker1,Deborah B.Horn2,Christine S.Fuchs Jacobsen3,Swathi Gopal4,Maria Quiroga3*,Se。

3、Ravussin E et al.Presented at the 33rd European Congress on Obesity(ECO),May 1215,2026;Istanbul,Trkiye.REDEFINE 1:Effect of CagriSema 2.4 mg/2.4 mg on body composition,muscle strength and physical fu。

4、Le Roux et al.Presented at the 33rd European Congress on Obesity(ECO),1215 May 2026,Istanbul,TrkiyeOASIS 4:Efficacy of oral semaglutide25 mg in obesity treatment targets and low-risk outcomes for car。

5、CagriSema 2.4 mg/2.4 mg improves metabolic syndrome in adults with overweight or obesity,without type 2 diabetes:A post hoc analysis of REDEFINE 1Matthias Blher1*,Kasper Adelborg2,Melanie J.Davies3,I。

6、Busetto L et al.Presented at the 33rdEuropean Congress on Obesity(ECO),1215 May 2026,Istanbul,Trkiye.Efficacy and safety of semaglutide in individuals aged 65 years:A pooled analysis of the STEP tria。

7、Early responders to oral semaglutide 25 mg:A post hoc analysis of the OASIS 4 trialW.Timothy Garvey1,Oscar Birkhan2,Naveen Rathor2,Chaithra Shaji3,Domenica Rubino4PO4.274https:/ QR code or visit the 。

8、 PO4.218Aim To evaluate the effect of co-administration of oral or subcutaneous(s.c.)zenagamtide on the pharmacokinetics(PK)of a combined oral contraceptive(OC)pill.Introduction Glucagon-like peptide。

9、Renal or hepatic impairment does not affect the pharmacokinetics,safety or tolerability of subcutaneous cagrilintideMette J.F.Nielsen1,Niels-Peter Becker1,Helene H.Hansen Duus1,Katrine Kirkeby1,Viera。

10、Scan QR code or visit the web site below for:Digital posterhttps:/ V et al.Adv Ther 2025;42:53415364.1Department of Medicine,Faculty of Medicine and Dentistry,University of Alberta,Edmonton,AB,Canada。

11、Argyrakopoulou G et al.Presented at the 33rdEuropean Congress on Obesity(ECO),1215 May 2026,Istanbul,Trkiye.Time to sustainable weight reduction thresholds with semaglutide 7.2 mg in adults with obes。

12、1Novo Nordisk A/S,Sborg,Denmark;2Novo Nordisk Service Centre India Private Ltd,Bangalore,India;3Altasciences Inc.,Montreal,QC,Canada.This study was sponsored by Novo Nordisk A/S and is registered wit。

13、Mobile health appsTelehealthRemote monitoringScan QR code or visit the web site below for:Digital posterhttps:/ B et al.Nature Med 2025;31:33173329;(2)Al Mahmud A et al.JMIR Mhealth Uhealth 2026;14:e。

14、Blher M et al.Presented at the 33rd European Congress on Obesity(ECO 2026),1215 May 2026,Istanbul,Trkiye.Treatment effect of CagriSema 2.4 mg/2.4 mg in adults with early-onset overweight or obesity i。

15、Rubino D et al.Presented at the 33rdEuropean Congress on Obesity(ECO),1215 May 2026,Istanbul,Trkiye.Improved quality of life with CagriSema in people with overweight or obesity and poor physical func。

16、Cavender MA et al.Presented at the 33rdEuropean Congress on Obesity(ECO),1215 May 2026,Istanbul,TrkiyeAssessing cardiovascular safety and outcomes with the combination of cagrilintide and semaglutide。

17、Rubino D et al.Presented at the 33rdEuropean Congress on Obesity(ECO 2026),1215 May 2026,Istanbul,Trkiye.Gastrointestinal tolerability of once-daily oral semaglutide 25 mg in adults with overweight o。

18、Vallis M et al.Presented at the 33rdEuropean Congress on Obesity(ECO),1215 May 2026,Istanbul,Trkiye.Characteristics,attitudes and experiences of individuals using injectable semaglutide for obesity m。

19、Verma S.et al.Presented at the 33rd European Congress on Obesity(ECO),May 1215,2026;Istanbul,Trkiye.CagriSema reduces predicted atherosclerotic cardiovascular disease risk in adults with overweight o。

20、Luca Busetto et al.Presented at the 33rd European Congress on Obesity(ECO),May 1215,2026;Istanbul,Trkiye.Scan QR code or visit the website below for:Science Hub linkshttps:/ and achievement of BMI an。

21、Scan QR code or visit the web site below for:Digital posterhttps:/ CONSTANCES French national cohort.Available at:http:/doi.org/10.13143/inserm_constances(accessed May 2026);(2)Zins M,Goldberg M,and 。

22、Garvey WT et al.Presented at the 33rdEuropean Congress on Obesity(ECO),1215 May 2026,Istanbul,Trkiye.Relationship between mean CagriSema dose and weight loss in the REDEFINE 1 trialW.Timothy Garvey1,。

23、1Department of Internal Medicine,Division of Endocrinology and Peter O Donnell Jr.School of Public Health,University of Texas Southwestern Medical Center,Dallas,TX,USA;2Institute of Cardiovascular Sc。

24、PO4.256Aim To characterise CagriSema dose reductions in the REDEFINE 1study to improve understanding of their timing and associatedclinical factors.Introduction In the REDEFINE 1 trial,treatment with。